NTRA (Natera, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by NTRA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-28 | John Fesko | PRESIDENT, CHIEF BUS. OFFICER | MIXED | — | — |
| 2026-08-14 | Jonathan Sheena | Director | Sell | — | — |
| 2026-08-07 | Jonathan Sheena | Director | Sell | — | — |
| 2026-08-07 | Matthew Rabinowitz | EXECUTIVE CHAIRMAN | Sell | — | — |
| 2026-08-07 | Matthew Rabinowitz | EXECUTIVE CHAIRMAN | Sell | — | — |
| 2026-08-07 | Jonathan Sheena | Director | Sell | — | — |
| 2026-08-05 | John Fesko | PRESIDENT, CHIEF BUS. OFFICER | Sell | — | — |
| 2026-08-05 | Michael Burkes Brophy | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2026-08-05 | Steven Leonard Chapman | CEO AND PRESIDENT | Sell | — | — |
| 2026-08-05 | Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | Sell | — | — |
| 2026-08-05 | DANIEL RABINOWITZ | SEC. AND CHIEF LEGAL OFFICER | Sell | — | — |
| 2026-08-05 | Matthew Rabinowitz | EXECUTIVE CHAIRMAN | Sell | — | — |
| 2026-08-05 | Jonathan Sheena | Director | Sell | — | — |
| 2026-07-29 | Steven Leonard Chapman | CEO AND PRESIDENT | Sell | — | — |
| 2026-07-29 | DANIEL RABINOWITZ | SEC. AND CHIEF LEGAL OFFICER | Sell | — | — |
| 2026-07-29 | Michael Burkes Brophy | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2026-07-29 | Matthew Rabinowitz | EXECUTIVE CHAIRMAN | Sell | — | — |
| 2026-07-29 | Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | Sell | — | — |
| 2026-07-29 | John Fesko | PRESIDENT, CHIEF BUS. OFFICER | Sell | — | — |
| 2026-07-29 | Jonathan Sheena | Director | Sell | — | — |
| 2026-07-17 | Rowan E Chapman | Director | Sell | — | — |
| 2026-07-17 | Jonathan Sheena | Director | Sell | — | — |
| 2026-07-15 | Jonathan Sheena | Director | Sell | — | — |
| 2026-07-08 | Matthew Rabinowitz | EXECUTIVE CHAIRMAN | Sell | — | — |
| 2026-07-06 | Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | Sell | — | — |
| 2026-07-06 | DANIEL RABINOWITZ | SEC. AND CHIEF LEGAL OFFICER | Sell | — | — |
| 2026-06-26 | HERM ROSENMAN | Director | Sell | — | — |
| 2026-06-26 | DANIEL RABINOWITZ | SEC. AND CHIEF LEGAL OFFICER | Sell | — | — |
| 2026-06-22 | Jonathan Sheena | Director | Sell | — | — |
| 2026-06-17 | Rowan E Chapman | Director | Sell | — | — |
| 2026-06-17 | Jonathan Sheena | Director | Sell | — | — |
| 2026-06-16 | Matthew Rabinowitz | EXECUTIVE CHAIRMAN | Sell | — | — |
| 2026-06-09 | Gail Boxer Marcus | Director | MIXED | — | — |
| 2026-06-05 | Steven Leonard Chapman | CEO AND PRESIDENT | Sell | — | — |
| 2026-06-03 | ROELOF BOTHA | Director | Sell | — | — |
| 2026-06-03 | Eric H Rubin | Director | A | — | — |
| 2026-06-03 | Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | Sell | — | — |
| 2026-05-28 | John Fesko | PRESIDENT, CHIEF BUS. OFFICER | Sell | — | — |
| 2026-05-28 | Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | Sell | — | — |
| 2026-05-15 | Jonathan Sheena | Director | Sell | — | — |
| 2026-05-06 | Matthew Rabinowitz | EXECUTIVE CHAIRMAN | MIXED | — | — |
| 2026-05-05 | DANIEL RABINOWITZ | SEC. AND CHIEF LEGAL OFFICER | Sell | — | — |
| 2026-05-05 | Steven Leonard Chapman | CEO AND PRESIDENT | Sell | — | — |
| 2026-05-05 | John Fesko | PRESIDENT, CHIEF BUS. OFFICER | Sell | — | — |
| 2026-05-05 | Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | Sell | — | — |
| 2026-05-05 | Jonathan Sheena | Director | Sell | — | — |
| 2026-05-05 | Michael Burkes Brophy | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2026-04-29 | Jonathan Sheena | Director | Sell | — | — |
| 2026-04-29 | DANIEL RABINOWITZ | SEC. AND CHIEF LEGAL OFFICER | Sell | — | — |
| 2026-04-29 | Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,949,364 | — |
| — | EXECUTIVE CHAIRMAN | 2,277,394 | — |
| — | Director | 1,596,540 | — |
| — | Director | 1,079,092 | — |
| — | 10%+ Owner | 506,331 | — |
| — | 10%+ Owner | 253,242 | — |
| — | Director | 248,496 | — |
| — | PRESIDENT, CHIEF BUS. OFFICER | 197,257 | — |
| — | SEC. AND CHIEF LEGAL OFFICER | 170,073 | — |
| — | CHIEF OPERATING OFFICER | 138,232 | — |
| — | PRESIDENT, CLINICALDIAGNOSTICS | 132,019 | — |
| — | CEO AND PRESIDENT | 100,805 | — |
| — | Director | 56,791 | — |
| — | Director | 52,009 | — |
| — | CHIEF FINANCIAL OFFICER | 51,637 | — |
| — | Director | 18,512 | — |
| — | Director | 15,813 | — |
| — | 10%+ Owner | 7,151 | — |
| — | Director | 6,183 | — |
| — | Director | 5,475 | — |
| — | Director | 5,374 | — |
| — | Director | 4,663 | — |
| — | Director | 4,250 | — |
| — | Director | 2,129 | — |
| — | 10%+ Owner | 495 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NTRA quote page; the site-wide leaderboard is on the insider transactions hub.